


BRYOMASTER[®]

BryoMaster delivers biopharmaceutical proteins using a cGMP-compliant production process based on moss.

BryoMaster offers an improved solution targeting difficult-to-express proteins.

BryoMaster enables development of stable production strains cultivated in a photoautotrophic fermentation process for production of large scale batches of pharmaceutical proteins such as LSD-enzymes, ADCC-enhanced mAbs, and immunotoxins.


High quality protein samples and clinical grade pharmaceuticals



Strain development and cGMP-compliant protein production with BryoMaster®


When you need a stable process for expression of a difficult-to-express protein, BryoMaster offers a photoautotrophic fermentation process in a purely mineral medium free of antibiotics and animal-derived components.

The process is highly flexible in scale and allows for straightforward tech transfer to any given environment. As a result you get clinical material or a master cell bank or we transfer the cGMP production process to your site.



01. Feasibility

- vector design
- small scale expression



02. BryoMaster

- strain and process development
- cell banking
- production process development



03. cGMP-compliant production

- contract manufacturing




Figure: Greenovation's contract development and manufacturing services

BryoMaster delivers better products:

- Genetically stable strains
- GlycodeSIGN
- Batch to batch stability
- Animal component free
- Antibiotic free
- Customized platforms



DO IT IN MOSS

BryoTechnology offers a wide range of advantages for biopharmaceutical development and production processes. Our broad IP portfolio covers plant production processes, N-glycosylation techniques, proprietary drug candidates, and mechanisms-of-action. We offer contract manufacturing and licensing models.

CONTACT

Manon Kirstein
Head of Business Development
Phone + 49 761 470 99 0
bd@greenovation.com
www.greenovation.com